Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of VSA003 injection in Chinese adolescents and adults with homozygous familial hypercholesterolemia
CTR20244397Phase 3Active
- Sponsor
- Visirna Therapeutics
- Start
- Dec 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zodasiran in familial hypercholesterolemia (FH), sponsored by Visirna Therapeutics. Started Dec 2024; status: active.
02
Drugs
zodasiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20244397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244397.